Effect of meconium ileus on the clinical prognosis of patients with cystic fibrosis

The objective of the present study was to determine the possible prognostic factors which may explain the difference in the survival of patients with cystic fibrosis (CF) with and without meconium ileus. Over a period of 20 years, 127 patients with CF, whose diagnosis was confirmed by typical clinical characteristics and altered sweat chloride levels, were studied retrospectively. The patients were divided into two groups: group 1 consisted of patients who presented CF and meconium ileus (N = 9), and group 2 consisted of patients with CF without meconium ileus (N = 118). The characteristics studied were based on data obtained upon admission of the patients using a specific protocol. Demographic, clinical, nutritional and laboratory data were obtained. The genotype was determined in 106 patients by PCR. Survival was analyzed using the Kaplan-Meier method. The median follow-up period was 44 months. A statistically significant difference was observed between the groups studied regarding the following variables: age at diagnosis and weight and height z scores. The presence of meconium ileus was associated with an earlier diagnosis; these patients had greater deficits in height and weight at the time of diagnosis and at the end of the study. The estimated probability of survival for patients with CF without meconium ileus was 62 ± 14% and for those with meconium ileus 32 ± 18%. Patients with CF and meconium ileus presented a poor nutritional status at diagnosis and a lower survival rate compared to the general CF population

p.F508del in a heterogeneous cystic fibrosis population from Minas Gerais, Brazil

Cystic fibrosis (CF) is the most common autosomal recessive disease of the Caucasian population. Among the various CF mutations, p.F508del is the most frequent, accounting for two-thirds of the global CF chromosomes, although showing great variability among populations. We have studied 115 unrelated CF patients from a mixed population of Minas Gerais (Brazil). To evaluate part of the DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, blood DNA was obtained and PCR was performed using two pairs of primers that anneal to exons 10 and 24 of the CFTR gene. The PCR product was then submitted to automatic sequencing using the ABI PRISM 310 Genetic Analyzer. The p.F508del mutation was found in 50 (21.7%) of 230 unrelated CF alleles. Fifteen (13.0%) patients were homozygous for this mutation, while 20 (17.4%) were heterozygous; the remaining 80 (69.6%) patients did not carry the p.F508del mutation. Exon 24 sequence had no change in 75 (65.2%) patients, 21 (18.3%) had the sequence variation 4521G/A, 11 (9.6%) had a not yet described sequence variation 4407T/A and 8 (7.0%) patients had both sequence variations (4521G/A and 4407T/A). The polymorphism 4407T/A results in an amino acid modification from aspartic acid to glutamic acid, which will probably have no function effect in CFTR. This low p.F508del prevalence can be due to the variable ethnic origin of this population from Minas Gerais, which may have a high diversity of CF rare mutations

Pseudomonas Aeruginosa Infection In Patients With Cystic Fibrosis: Scientific Evidence Regarding Clinical Impact, Diagnosis, And Treatment [infecção Por Pseudomonas Aeruginosa Em Pacientes Com Fibrose Cística: Evidências Científicas Sobre O Impacto Clínico, Diagnóstico E Tratamento]

Evidence-based techniques have been increasingly used in the creation of clinical guidelines and the development of recommendations for medical practice. The use of levels of evidence allows the reader to identify the quality of scientific information that supports the recommendations made by experts. The objective of this review was to address current concepts related to the clinical impact, diagnosis, and treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. For the preparation of this review, the authors defined a group of questions that would be answered in accordance with the principles of PICO-an acronym based on questions regarding the Patients of interest, Intervention being studied, Comparison of the intervention, and Outcome of interest. For each question, a structured review of the literature was performed using the Medline database in order to identify the studies with the methodological design most appropriate to answering the question. The questions were designed so that each of the authors could write a response. A first draft was prepared and discussed by the group. Recommendations were then made on the basis of the level of scientific evidence, in accordance with the classification system devised by the Oxford Centre for Evidence-Based Medicine, as well as the level of agreement among the members of the group.394495512Ratjen, F., Döring, G., Cystic fibrosis (2003) Lancet, 361 (9358), pp. 681-689. , http://dx.doi.org/10.1016/S0140-6736(03)12567-6Flume, P.A., O'Sullivan, B.P., Robinson, K.A., Goss, C.H., Mogayzel Jr., P.J., Willey-Courand, D.B., Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health (2007) Am J Respir Crit Care Med, 176 (10), pp. 957-969. , http://dx.doi.org/10.1164/rccm.200705-664OC, PMid:17761616Ratjen, F.A., Cystic fibrosis: Pathogenesis and future treatment strategies (2009) Respir Care, 54 (5), pp. 595-605. , http://dx.doi.org/10.4187/aarc0427, PMid:19393104Lommatzsch, S.T., Aris, R., Genetics of cystic fibrosis (2009) Semin Respir Crit Care Med, 30 (5), pp. 531-538. , http://dx.doi.org/10.1055/s-0029-1238911, PMid:19760540Ratjen, F., Diagnosing and managing infection in CF Paediatr Respir Rev. 2006;7 Suppl, 1, pp. 151-153. , http://dx.doi.org/10.1016/j.prrv.2006.04.217, PMid:16798546Govan, J.R., Deretic, V., Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia (1996) Microbiol Rev, 60 (3), pp. 539-574. , PMid:8840786 PMCid:239456Li, Z., Kosorok, M.R., Farrell, P.M., Laxova, A., West, S.E., Green, C.G., Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis (2005) JAMA, 293 (5), pp. 581-588. , http://dx.doi.org/10.1001/jama.293.5.581, PMid:15687313Gibson, R.L., Burns, J.L., Ramsey, B.W., Pathophysiology and management of pulmonary infections in cystic fibrosis (2003) Am J Respir Crit Care Med, 168 (8), pp. 918-951. , http://dx.doi.org/10.1164/rccm.200304-505SO, PMid:14555458Deschaght, P., van Daele, S., de Baets, F., Vaneechoutte, M., PCR and the detection of Pseudomonas aeruginosa in respiratory samples of CF patients. A literature review (2011) J Cyst Fibros, 10 (5), pp. 293-297. , http://dx.doi.org/10.1016/j.jcf.2011.05.004, PMid:21684819Nixon, G.M., Armstrong, D.S., Carzino, R., Carlin, J.B., Olinsky, A., Robertson, C.F., Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis (2001) J Pediatr, 138 (5), pp. 699-704. , http://dx.doi.org/10.1067/mpd.2001.112897, PMid:11343046Henry, R.L., Mellis, C.M., Petrovic, L., Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis (1992) Pediatr Pulmonol, 12 (3), pp. 158-161. , http://dx.doi.org/10.1002/ppul.1950120306, PMid:1641272Taccetti, G., Campana, S., Festini, F., Mascherini, M., Döring, G., Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients (2005) Eur Respir J, 26 (3), pp. 458-461. , http://dx.doi.org/10.1183/09031936.05.00009605, PMid:16135728The Oxford 2011 Levels of Evidence, , http://www.cebm.net/index.aspx?o=5653, CEBM Centre For Evidence Based Medicine [homepage on the Internet]. Oxford: University of Oxford. [cited 2013 Feb 11]Lee, T.W., Brownlee, K.G., Conway, S.P., Denton, M., Littlewood, J.M., Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients (2003) J Cyst Fibros, 2 (1), pp. 29-34. , http://dx.doi.org/10.1016/S1569-1993(02)00141-8Corey, M., Survival estimates in cystic fibrosis: Snapshots of a moving target (1996) Pediatr Pulmonol, 21 (3), pp. 149-150. , http://dx.doi.org/10.1002/1099-0496(199603)21:3149::AID-PPUL19502103023.0.CO;2-CHudson, V.L., Wielinski, C.L., Regelmann, W.E., Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years (1993) J Pediatr, 122 (6), pp. 854-860. , http://dx.doi.org/10.1016/S0022-3476(09)90007-5Kosorok, M.R., Zeng, L., West, S.E., Rock, M.J., Splaingard, M.L., Laxova, A., Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition (2001) Pediatr Pulmonol, 32 (4), pp. 277-287. , http://dx.doi.org/10.1002/ppul.2009.abs, PMid:11568988Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., Gibson, R.L., Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis (2002) Pediatr Pulmonol, 34 (2), pp. 91-100. , http://dx.doi.org/10.1002/ppul.10127, PMid:12112774Lebecque, P., Leal, T., Zylberberg, K., Reychler, G., Bossuyt, X., Godding, V., Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis (2006) J Cyst Fibros, 5 (4), pp. 237-244. , http://dx.doi.org/10.1016/j.jcf.2006.04.001, PMid:16790367Ratjen, F., Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis (2006) Curr Opin Pulm Med, 12 (6), pp. 428-432. , http://dx.doi.org/10.1097/01.mcp.0000245712.51514.a1, PMid:17053493Equi, A.C., Pike, S.E., Davies, J., Bush, A., Use of cough swabs in a cystic fibrosis clinic (2001) Arch Dis Child, 85 (5), pp. 438-439. , http://dx.doi.org/10.1136/adc.85.5.438, PMid:11668115 PMCid:1718986Da Silva Filho, L.V., Tateno, A.F., Martins, K.M., Azzuz Chernishev, A.C., de Garcia, D.O., Haug, M., The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis (2007) Pediatr Pulmonol, 42 (10), pp. 938-944. , http://dx.doi.org/10.1002/ppul.20686, PMid:17722007Hoiby, N., Flensborg, E.W., Beck, B., Friis, B., Jacobsen, S.V., Jacobsen, L., Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis (1977) Scand J Respir Dis, 58 (2), pp. 65-79. , PMid:404701Brett, M.M., Ghoneim, A.T., Littlewood, J.M., Prediction and diagnosis of early Pseudomonas aeruginosa infection in cystic fibrosis: A follow-up study (1988) J Clin Microbiol, 26 (8), pp. 1565-1570. , Erratum in: J Clin Microbiol 1989;27(1):230. PMid:3139707 PMCid:266661West, S.E., Zeng, L., Lee, B.L., Kosorok, M.R., Laxova, A., Rock, M.J., Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: Early detection by serology and assessment of risk factors (2002) JAMA, 287 (22), pp. 2958-2967. , http://dx.doi.org/10.1001/jama.287.22.2958, PMid:12052125Kappler, M., Kraxner, A., Reinhardt, D., Ganster, B., Griese, M., Lang, T., Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis (2006) Thorax, 61 (8), pp. 684-688. , http://dx.doi.org/10.1136/thx.2005.049536, PMid:16449259 PMCid:2104684Tramper-Stranders, G.A., van der Ent, C.K., Slieker, M.G., Terheggen-Lagro, S.W., Teding van Berkhout, F., Kimpen, J.L., Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population (2006) Thorax, 61 (8), pp. 689-693. , http://dx.doi.org/10.1136/thx.2005.054726, PMid:16601093 PMCid:2104678Ratjen, F., Walter, H., Haug, M., Meisner, C., Grasemann, H., Döring, G., Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients (2007) Pediatr Pulmonol, 42 (3), pp. 249-255. , http://dx.doi.org/10.1002/ppul.20562, PMid:17243185Weisner, A.M., Chart, H., Bush, A., Davies, J.C., Pitt, T.L., Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis (2007) J Med Microbiol, 56 (PART 5), pp. 670-674. , http://dx.doi.org/10.1099/jmm.0.46833-0, PMid:17446292Pressler, T., Karpati, F., Granström, M., Knudsen, P.K., Lindblad, A., Hjelte, L., Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods (2009) J Cyst Fibros, 8 (1), pp. 37-42. , http://dx.doi.org/10.1016/j.jcf.2008.08.002, PMid:18835753Milagres, L.G., Castro, T.L., Garcia, D., Cruz, A.C., Higa, L., Folescu, T., Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis (2009) Pediatr Pulmonol, 44 (4), pp. 392-401. , http://dx.doi.org/10.1002/ppul.21022, PMid:19283764Hayes Jr., D., Farrell, P.M., Li, Z., West, S.E., Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening (2010) Pediatr Pulmonol, 45 (1), pp. 55-61. , http://dx.doi.org/10.1002/ppul.21083, PMid:20025049 PMCid:2924665Douglas, T.A., Brennan, S., Berry, L., Winfield, K., Wainwright, C.E., Grimwood, K., Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis (2010) Thorax, 65 (11), pp. 985-990. , http://dx.doi.org/10.1136/thx.2009.132845, PMid:20889526Wainwright, C.E., Vidmar, S., Armstrong, D.S., Byrnes, C.A., Carlin, J.B., Cheney, J., Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: A randomized trial (2011) JAMA, 306 (2), pp. 163-171. , http://dx.doi.org/10.1001/jama.2011.954, PMid:21750293Littlewood, J.M., Miller, M.G., Ghoneim, A.T., Ramsden, C.H., Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis (1985) Lancet, 1 (8433), p. 865. , http://dx.doi.org/10.1016/S0140-6736(85)92222-6Valerius, N.H., Koch, C., Høiby, N., Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment (1991) Lancet, 338 (8769), pp. 725-726. , http://dx.doi.org/10.1016/0140-6736(91)91446-2Munck, A., Bonacorsi, S., Mariani-Kurkdjian, P., Lebourgeois, M., Gérardin, M., Brahimi, N., Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization (2001) Pediatr Pulmonol, 32 (4), pp. 288-292. , http://dx.doi.org/10.1002/ppul.1121, PMid:11568989Gibson, R.L., Emerson, J., McNamara, S., Burns, J.L., Rosenfeld, M., Yunker, A., Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis (2003) Am J Respir Crit Care Med, 167 (6), pp. 841-849. , http://dx.doi.org/10.1164/rccm.200208-855OC, PMid:12480612Davidson, A.G., Chilvers, M.A., Lillquist, Y.P., Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic (2012) Curr Opin Pulm Med, 18 (6), pp. 615-621. , http://dx.doi.org/10.1097/MCP.0b013e328358f5a2, PMid:22990661Ratjen, F., Munck, A., Kho, P., Angyalosi, G., ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial (2010) Thorax, 65 (4), pp. 286-291. , http://dx.doi.org/10.1136/thx.2009.121657, PMid:19996339Treggiari, M.M., Retsch-Bogart, G., Mayer-Hamblett, N., Khan, U., Kulich, M., Kronmal, R., Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis (2011) Arch Pediatr Adolesc Med, 165 (9), pp. 847-856. , http://dx.doi.org/10.1001/archpediatrics.2011.136, PMid:21893650Langton Hewer, S.C., Smyth, A.R., Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (2009) Cochrane Database Syst Rev, (4), pp. CD004197. , PMid:19821321Collaco, J.M., Green, D.M., Cutting, G.R., Naughton, K.M., Mogayzel Jr., P.J., Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes (2010) Am J Respir Crit Care Med, 182 (9), pp. 1137-1143. , http://dx.doi.org/10.1164/rccm.201001-0057OC, PMid:20581166 PMCid:3001256Fuchs, H.J., Borowitz, D.S., Christiansen, D.H., Morris, E.M., Nash, M.L., Ramsey, B.W., Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group (1994) N Engl J Med, 331 (10), pp. 637-642. , http://dx.doi.org/10.1056/NEJM199409083311003, PMid:7503821Rosenfeld, M., Emerson, J., Williams-Warren, J., Pepe, M., Smith, A., Montgomery, A.B., Defining a pulmonary exacerbation in cystic fibrosis (2001) J Pediatr, 139 (3), pp. 359-365. , http://dx.doi.org/10.1067/mpd.2001.117288, PMid:11562614Dakin, C., Henry, R.L., Field, P., Morton, J., Defining an exacerbation of pulmonary disease in cystic fibrosis (2001) Pediatr Pulmonol, 31 (6), pp. 436-442. , http://dx.doi.org/10.1002/ppul.1072, PMid:11389576Flume, P.A., Mogayzel Jr., P.J., Robinson, K.A., Goss, C.H., Rosenblatt, R.L., Kuhn, R.J., Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations (2009) Am J Respir Crit Care Med, 180 (9), pp. 802-808. , http://dx.doi.org/10.1164/rccm.200812-1845PP, PMid:19729669Stenbit, A.E., Flume, P.A., Pulmonary exacerbations in cystic fibrosis (2011) Curr Opin Pulm Med, 17 (6), pp. 442-447. , PMid:21881509Bilton, D., Canny, G., Conway, S., Dumcius, S., Hjelte, L., Proesmans, M., Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials (2011) J Cyst Fibros, 10 (SUPPL. 2), pp. 79-81. , http://dx.doi.org/10.1016/S1569-1993(11)60012-XBalaguer, A., De Dios, G.J., Home versus hospital intravenous antibiotic therapy for cystic fibrosis (2012) Cochrane Database Syst Rev, 3, pp. CD001917. , PMid:22419283Smyth, A., Elborn, J.S., Exacerbations in cystic fibrosis: 3. Management (2008) Thorax, 63 (2), pp. 180-184. , http://dx.doi.org/10.1136/thx.2006.060905, PMid:18234661Smyth, A., Knox, A., Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis (2011) J Cyst Fibros, 10 (5), p. 383. , http://dx.doi.org/10.1016/j.jcf.2011.03.010, PMid:21507733Breidenstein, E.B., de la Fuente-Nú-ez, C., Hancock, R.E., Pseudomonas aeruginosa: All roads lead to resistance (2011) Trends Microbiol, 19 (8), pp. 419-426. , http://dx.doi.org/10.1016/j.tim.2011.04.005, PMid:21664819Cheng, K., Smyth, R.L., Govan, J.R., Doherty, C., Winstanley, C., Denning, N., Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic (1996) Lancet, 348 (9028), pp. 639-642. , http://dx.doi.org/10.1016/S0140-6736(96)05169-0Elphick, H.E., Tan, A., Single versus combination intravenous antibiotic therapy for people with cystic fibrosis (2005) Cochrane Database Syst Rev, (2), pp. CD002007. , PMid:15846627Bosso, J.A., Saxon, B.A., Matsen, J.M., Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients (1991) Antimicrob Agents Chemother, 35 (4), pp. 783-784. , http://dx.doi.org/10.1128/AAC.35.4.783, PMid:1906264 PMCid:245101Tré-Hardy, M., Nagant, C., El-Manssouri, N., Vanderbist, F., Traore, H., Vaneechoutte, M., Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model (2010) Antimicrob Agents Chemother, 54 (10), pp. 4409-4415. , http://dx.doi.org/10.1128/AAC.00372-10, PMid:20696878 PMCid:2944582Leroy, A., Humbert, G., Oksenhendler, G., Fillastre, J.P., Pharmacokinetics of aminoglycosides in subjects with normal and impaired renal function (1978) Antibiot Chemother, 25, pp. 163-180. , PMid:352252Kovarik, J.M., Hoepelman, I.M., Verhoef, J., Once-daily aminoglycoside administration: New strategies for an old drug (1989) Eur J Clin Microbiol Infect Dis, 8 (9), pp. 761-769. , http://dx.doi.org/10.1007/BF02185842, PMid:2512146Freeman, C.D., Nicolau, D.P., Belliveau, P.P., Nightingale, C.H., Once-daily dosing of aminoglycosides: Review and recommendations for clinical practice (1997) J Antimicrob Chemother, 39 (6), pp. 677-686. , http://dx.doi.org/10.1093/jac/39.6.677, PMid:9222035Contopoulos-Ioannidis, D.G., Giotis, N.D., Baliatsa, D.V., Ioannidis, J.P., Extended-interval aminoglycoside administration for children: A meta-analysis (2004) Pediatrics, 114 (1), pp. 111-118. , http://dx.doi.org/10.1542/peds.114.1.e111, PMid:15231982Smyth, A.R., Bhatt, J., Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis (2012) Cochrane Database Syst Rev, 2, pp. CD002009. , PMid:22336782Plummer, A., Wildman, M., Duration of intravenous antibiotic therapy in people with cystic fibrosis (2011) Cochrane Database Syst Rev, 1, pp. CD006682. , PMid:21249681Vandevanter, D.R., O'Riordan, M.A., Blumer, J.L., Konstan, M.W., Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations (2010) Respir Res, 11, p. 137. , http://dx.doi.org/10.1186/1465-9921-11-137, PMid:20925941 PMCid:2959026Hodson, M.E., Penketh, A.R., Batten, J.C., Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis (1981) Lancet, 2 (8256), pp. 1137-1139. , http://dx.doi.org/10.1016/S0140-6736(81)90588-2Szaff, M., Høiby, N., Flensborg, E.W., Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection (1983) Acta Paediatr Scand, 72 (5), pp. 651-657. , http://dx.doi.org/10.1111/j.1651-2227.1983.tb09789.x, PMid:6637463Ramsey, B.W., Dorkin, H.L., Eisenberg, J.D., Gibson, R.L., Harwood, I.R., Kravitz, R.M., Efficacy of aerosolized tobramycin in patients with cystic fibrosis (1993) N Engl J Med, 328 (24), pp. 1740-1746. , http://dx.doi.org/10.1056/NEJM199306173282403, PMid:8497284Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J., Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group (1999) N Engl J Med, 340 (1), pp. 23-30. , http://dx.doi.org/10.1056/NEJM199901073400104, PMid:9878641Maclusky, I.B., Gold, R., Corey, M., Levison, H., Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa (1989) Pediatr Pulmonol, 7 (1), pp. 42-48. , http://dx.doi.org/10.1002/ppul.1950070110, PMid:2505216Murphy, T.D., Anbar, R.D., Lester, L.A., Nasr, S.Z., Nickerson, B., Vandevanter, D.R., Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease (2004) Pediatr Pulmonol, 38 (4), pp. 314-320. , http://dx.doi.org/10.1002/ppul.20097, PMid:15334509(2009) Antibiotic Treatment For Cystic Fibrosis, , https://www.cysticfibrosis.org.uk/media/82010/CD_Antibiotic_treatment_for_CF_May_09.pdf, Cystic Fibrosis Trust [homepage on the Internet]. Bromley: Cystic Fibrosis Trust. [cited 2013 Feb 11], [Adobe Acrobat document, 102p.]Hodson, M.E., Gallagher, C.G., Govan, J.R., A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis (2002) Eur Respir J, 20 (3), pp. 658-664. , http://dx.doi.org/10.1183/09031936.02.00248102, PMid:12358344McCoy, K.S., Quittner, A.L., Oermann, C.M., Gibson, R.L., Retsch-Bogart, G.Z., Montgomery, A.B., Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis (2008) Am J Respir Crit Care Med, 178 (9), pp. 921-928. , http://dx.doi.org/10.1164/rccm.200712-1804OC, PMid:18658109 PMCid:2577727Oermann, C.M., Retsch-Bogart, G.Z., Quittner, A.L., Gibson, R.L., McCoy, K.S., Montgomery, A.B., An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis (2010) Pediatr Pulmonol, 45 (11), pp. 1121-1134. , http://dx.doi.org/10.1002/ppul.21301, PMid:20672296Konstan, M.W., Flume, P.A., Kappler, M., Chiron, R., Higgins, M., Brockhaus, F., Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial (2011) J Cyst Fibros, 10 (1), pp. 54-61. , http://dx.doi.org/10.1016/j.jcf.2010.10.003, PMid:21075062Geller, D.E., Flume, P.A., Staab, D., Fischer, R., Loutit, J.S., Conrad, D.J., Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa (2011) Am J Respir Crit Care Med, 183 (11), pp. 1510-1516. , http://dx.doi.org/10.1164/rccm.201008-1293OC, PMid:21471106Ryan, G., Singh, M., Dwan, K., Inhaled antibiotics for long-term therapy in cystic fibrosis (2011) Cochrane Database Syst Rev, (3), pp. CD001021Sawicki, G.S., Tiddens, H., Managing treatment complexity in cystic fibrosis: Challenges and opportunities (2012) Pediatr Pulmonol, 47 (6), pp. 523-533. , http://dx.doi.org/10.1002/ppul.22546, PMid:22467341Robinson, P., Cystic fibrosis (2001) Thorax, 56 (3), pp. 237-241. , http://dx.doi.org/10.1136/thorax.56.3.237, PMid:11182019 PMCid:1758774Bell, S.C., Robinson, P.J., Exacerbations in cystic fibrosis: 2. prevention (2007) Thorax, 62 (8), pp. 723-732. , http://dx.doi.org/10.1136/thx.2006.060897, PMid:17687099 PMCid:2117269Sawicki, G.S., Sellers, D.E., Robinson, W.M., High treatment burden in adults with cystic fibrosis: Challenges to disease self-management (2009) J Cyst Fibros, 8 (2),